We have located links that may give you full text access.
JOURNAL ARTICLE
RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
Intake of alcohol and alcoholic beverages and the risk of basal cell carcinoma of the skin.
Cancer Epidemiology, Biomarkers & Prevention 2002 October
We prospectively examined the intake of alcoholic beverages in relation to the risk of basal cell carcinoma BCC in two large cohorts of men and women. Alcohol intake was assessed with food frequency questionnaires every 2-4 years, and BCC was ascertained by self-report. We used a pooled logistic regression to model the association between alcohol intake and BCC adjusting for various health, sun exposure, and sun-sensitivity factors. During 8 years of follow-up in women (1986-1994) we recorded 3060 cases of BCC, and during 10 years (1986-1996), we recorded 3028 cases in men. Significant positive associations were observed between total alcohol intake (P for trend <0.0001), alcohol from liquor (P for trend = 0.003), and white wine (P for trend = 0.01) intake and risk of BCC. Compared with those who abstained, those who drank 0.1-4.9 g, 5.0-14.9 g, 15.0-14.9 g, and 30 g or more alcohol a day had multivariate relative risks of 1.11 [95% confidence interval (CI), 1.03, 1.19], 1.26 (95% CI, 1.12, 1.41), 1.29 (95% CI, 1.18, 1.42), and 1.12 (95% CI, 1.01, 1.26), respectively. Alcohol from beer had no association with BCC in either cohort, and red wine appeared to have an inverse association in women (P for trend = 0.004) but not in men. These associations remained unchanged after adjustment for individual vitamins, multivitamin use, outdoor walking, and exclusion of follow-up time after last physical examination among those who never had BCC. Alcohol intake was associated with BCC, but the association appeared to be different for each type of alcoholic beverage. Other studies are needed to confirm these results.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app